168 related articles for article (PubMed ID: 26301626)
1. Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase δ for the Treatment of Respiratory Disease.
Down K; Amour A; Baldwin IR; Cooper AW; Deakin AM; Felton LM; Guntrip SB; Hardy C; Harrison ZA; Jones KL; Jones P; Keeling SE; Le J; Livia S; Lucas F; Lunniss CJ; Parr NJ; Robinson E; Rowland P; Smith S; Thomas DA; Vitulli G; Washio Y; Hamblin JN
J Med Chem; 2015 Sep; 58(18):7381-99. PubMed ID: 26301626
[TBL] [Abstract][Full Text] [Related]
2. Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD.
Cahn A; Hamblin JN; Begg M; Wilson R; Dunsire L; Sriskantharajah S; Montembault M; Leemereise CN; Galinanes-Garcia L; Watz H; Kirsten AM; Fuhr R; Hessel EM
Pulm Pharmacol Ther; 2017 Oct; 46():69-77. PubMed ID: 28823947
[TBL] [Abstract][Full Text] [Related]
3. Translation of Inhaled Drug Optimization Strategies into Clinical Pharmacokinetics and Pharmacodynamics Using GSK2292767A, a Novel Inhaled Phosphoinositide 3-Kinase
Begg M; Edwards CD; Hamblin JN; Pefani E; Wilson R; Gilbert J; Vitulli G; Mallett D; Morrell J; Hingle MI; Uddin S; Ehtesham F; Marotti M; Harrell A; Newman CF; Fernando D; Clark J; Cahn A; Hessel EM
J Pharmacol Exp Ther; 2019 Jun; 369(3):443-453. PubMed ID: 30940692
[TBL] [Abstract][Full Text] [Related]
4. Relationship between Pharmacokinetics and Pharmacodynamic Responses in Healthy Smokers Informs a Once-Daily Dosing Regimen for Nemiralisib.
Begg M; Wilson R; Hamblin JN; Montembault M; Green J; Deans A; Amour A; Worsley S; Fantom K; Cui Y; Dear G; Ahmad S; Kielkowska A; Clark J; Boyce M; Cahn A; Hessel EM
J Pharmacol Exp Ther; 2019 Jun; 369(3):337-344. PubMed ID: 30886125
[TBL] [Abstract][Full Text] [Related]
5. Characterizing Pharmacokinetic-Pharmacodynamic Relationships and Efficacy of PI3K
McLeod RL; Gil MA; Chen D; Cabal A; Katz J; Methot J; Woodhouse JD; Dorosh L; Geda P; Mehta K; Cicmil M; Baltus GA; Bass A; Houshyar H; Caniga M; Yu H; Gervais F; Alves S; Shah S
J Pharmacol Exp Ther; 2019 May; 369(2):223-233. PubMed ID: 30804001
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and SAR of indazole and benzoisoxazole containing 4-azetidinyl-1-aryl-cyclohexanes as CCR2 antagonists.
Zhang X; Hufnagel H; Hou C; Opas E; McKenney S; Crysler C; O'Neill J; Johnson D; Sui Z
Bioorg Med Chem Lett; 2011 Oct; 21(20):6042-8. PubMed ID: 21917454
[TBL] [Abstract][Full Text] [Related]
7. Discovery of (
Li F; Liang X; Jiang Z; Wang A; Wang J; Chen C; Wang W; Zou F; Qi Z; Liu Q; Hu Z; Cao J; Wu H; Wang B; Wang L; Liu J; Liu Q
J Med Chem; 2020 Nov; 63(22):13973-13993. PubMed ID: 33180507
[TBL] [Abstract][Full Text] [Related]
8. Aminopyridinecarboxamide-based inhaled IKK-2 inhibitors for asthma and COPD: Structure-activity relationship.
Xie J; Poda GI; Hu Y; Chen NX; Heier RF; Wolfson SG; Reding MT; Lennon PJ; Kurumbail RG; Selness SR; Li X; Kishore NN; Sommers CD; Christine L; Bonar SL; Venkatraman N; Mathialagan S; Brustkern SJ; Huang HC
Bioorg Med Chem; 2011 Feb; 19(3):1242-55. PubMed ID: 21236687
[TBL] [Abstract][Full Text] [Related]
9. Optimization of Orally Bioavailable PI3Kδ Inhibitors and Identification of Vps34 as a Key Selectivity Target.
Henley ZA; Amour A; Barton N; Bantscheff M; Bergamini G; Bertrand SM; Convery M; Down K; Dümpelfeld B; Edwards CD; Grandi P; Gore PM; Keeling S; Livia S; Mallett D; Maxwell A; Price M; Rau C; Reinhard FBM; Rowedder J; Rowland P; Taylor JA; Thomas DA; Hessel EM; Hamblin JN
J Med Chem; 2020 Jan; 63(2):638-655. PubMed ID: 31855425
[TBL] [Abstract][Full Text] [Related]
10. Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ-PI3Kδ Dual Inhibitors.
Jia H; Dai G; Su W; Xiao K; Weng J; Zhang Z; Wang Q; Yuan T; Shi F; Zhang Z; Chen W; Sai Y; Wang J; Li X; Cai Y; Yu J; Ren P; Venable J; Rao T; Edwards JP; Bembenek SD
J Med Chem; 2019 May; 62(10):4936-4948. PubMed ID: 31033293
[TBL] [Abstract][Full Text] [Related]
11. Structural Determinants of Isoform Selectivity in PI3K Inhibitors.
Miller MS; Thompson PE; Gabelli SB
Biomolecules; 2019 Feb; 9(3):. PubMed ID: 30813656
[TBL] [Abstract][Full Text] [Related]
12. Theoretical studies on beta and delta isoform-specific binding mechanisms of phosphoinositide 3-kinase inhibitors.
Zhu J; Pan P; Li Y; Wang M; Li D; Cao B; Mao X; Hou T
Mol Biosyst; 2014 Mar; 10(3):454-66. PubMed ID: 24336903
[TBL] [Abstract][Full Text] [Related]
13. Identification of 2-Imidazopyridine and 2-Aminopyridone Purinones as Potent Pan-Janus Kinase (JAK) Inhibitors for the Inhaled Treatment of Respiratory Diseases.
Bach J; Eastwood P; González J; Gómez E; Alonso JA; Fonquerna S; Lozoya E; Orellana A; Maldonado M; Calaf E; Albertí J; Pérez J; Andrés A; Prats N; Carreño C; Calama E; De Alba J; Calbet M; Miralpeix M; Ramis I
J Med Chem; 2019 Oct; 62(20):9045-9060. PubMed ID: 31609613
[TBL] [Abstract][Full Text] [Related]
14. Novel class of benzoic acid ester derivatives as potent PDE4 inhibitors for inhaled administration in the treatment of respiratory diseases.
Armani E; Amari G; Rizzi A; De Fanti R; Ghidini E; Capaldi C; Carzaniga L; Caruso P; Guala M; Peretto I; La Porta E; Bolzoni PT; Facchinetti F; Carnini C; Moretto N; Patacchini R; Bassani F; Cenacchi V; Volta R; Amadei F; Capacchi S; Delcanale M; Puccini P; Catinella S; Civelli M; Villetti G
J Med Chem; 2014 Feb; 57(3):793-816. PubMed ID: 24400806
[TBL] [Abstract][Full Text] [Related]
15. Evolution of a Novel, Orally Bioavailable Series of PI3Kδ Inhibitors from an Inhaled Lead for the Treatment of Respiratory Disease.
Amour A; Barton N; Cooper AW; Inglis G; Jamieson C; Luscombe CN; Morrell J; Peace S; Perez D; Rowland P; Tame CJ; Uddin S; Vitulli G; Wellaway N
J Med Chem; 2016 Aug; 59(15):7239-51. PubMed ID: 27429068
[TBL] [Abstract][Full Text] [Related]
16. Novel Inhaled Pan-JAK Inhibitor, LAS194046, Reduces Allergen-Induced Airway Inflammation, Late Asthmatic Response, and pSTAT Activation in Brown Norway Rats.
Calbet M; Ramis I; Calama E; Carreño C; Paris S; Maldonado M; Orellana A; Calaf E; Pauta M; De Alba J; Bach J; Miralpeix M
J Pharmacol Exp Ther; 2019 Aug; 370(2):137-147. PubMed ID: 31085698
[TBL] [Abstract][Full Text] [Related]
17. Application of an "inhalation by design" approach to the identification and in-vitro evaluation of novel purine based PI3Kδ inhibitors.
Mazzucato R; Roberti M; Capelli AM; Rancati F; Biagetti M; Fiorelli C; Bruno P; Ronchi P; Bertolini S; Corsi M; Pala D
Eur J Med Chem; 2023 Jun; 254():115331. PubMed ID: 37094451
[TBL] [Abstract][Full Text] [Related]
18. Discovery of GSK251: A Highly Potent, Highly Selective, Orally Bioavailable Inhibitor of PI3Kδ with a Novel Binding Mode.
Down K; Amour A; Anderson NA; Barton N; Campos S; Cannons EP; Clissold C; Convery MA; Coward JJ; Doyle K; Duempelfeld B; Edwards CD; Goldsmith MD; Krause J; Mallett DN; McGonagle GA; Patel VK; Rowedder J; Rowland P; Sharpe A; Sriskantharajah S; Thomas DA; Thomson DW; Uddin S; Hamblin JN; Hessel EM
J Med Chem; 2021 Sep; 64(18):13780-13792. PubMed ID: 34510892
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a Novel Series of N-Phenylindoline-5-sulfonamide Derivatives as Potent, Selective, and Orally Bioavailable Acyl CoA:Monoacylglycerol Acyltransferase-2 Inhibitors.
Sato K; Takahagi H; Yoshikawa T; Morimoto S; Takai T; Hidaka K; Kamaura M; Kubo O; Adachi R; Ishii T; Maki T; Mochida T; Takekawa S; Nakakariya M; Amano N; Kitazaki T
J Med Chem; 2015 May; 58(9):3892-909. PubMed ID: 25897973
[TBL] [Abstract][Full Text] [Related]
20. Discovery and optimization of indazoles as potent and selective interleukin-2 inducible T cell kinase (ITK) inhibitors.
Pastor RM; Burch JD; Magnuson S; Ortwine DF; Chen Y; De La Torre K; Ding X; Eigenbrot C; Johnson A; Liimatta M; Liu Y; Shia S; Wang X; Wu LC; Pei Z
Bioorg Med Chem Lett; 2014 Jun; 24(11):2448-52. PubMed ID: 24767842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
